102 research outputs found
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Qualitatssicherung Melanom: Leitlinienbasierte Qualitatsindikatoren beim Melanom - Implementierung, Evaluation und Update-Prozess
Quality assurance in melanoma care: guideline-based quality indicators for melanoma - implementation, evaluation and update process
Hematological immune related adverse events after treatment with immune checkpoint inhibitors
Tolerability of BRAF/MEK inhibitor combinations : adverse event evaluation and management
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Decision criteria and patient characteristics for patient-oriented treatment of field cancerization Standardized algorithm for personalized treatment concepts
- …